Premium
Effects of Mitomycin‐C on Normal Dermal Fibroblasts
Author(s) -
Chen Theodore,
Kunnavatana Shaun S.,
Koch R James
Publication year - 2006
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/01.mlg.0000205590.62824.0a
Subject(s) - mitomycin c , fibroblast , chemistry , microbiology and biotechnology , computational biology , biology , genetics , in vitro
Objectives: To evaluate the effects of mitomycin‐C on the growth and autocrine growth factor production of human dermal fibroblasts from the face. Study Design: In vitro study using normal adult dermal fibroblast cell lines in a serum‐free model. Methods: Cell cultures were exposed to 4 mg/mL, 0.4 mg/mL, 0.04 mg/mL, 0.004 mg/mL, and 0.0004 mg/mL concentrations of mitomycin‐C solution. Cell counts were performed, and the cell‐free supernatants were collected at 0, 1, 3, and 5 days after the initial exposure. Population doubling times were calculated and supernatants were quantitatively assayed for basic fibroblast growth factor (bFGF) and transforming growth factor (TGF)‐β1. Results: Continuous exposure to mitomycin‐C caused fibroblast cell death by day 7 at all tested concentrations. A 4 minute exposure to mitomycin‐C at 4 mg/mL caused rapid fibroblast cell death. A 4‐minute exposure to mitomycin‐C at either 0.4 mg/mL or 0.04 mg/mL resulted in decreased fibroblast proliferation. A 4 minute exposure to mitomycin‐C at 0.4 mg/mL resulted in a marked increase in the production of both bFGF and TGF‐β1. Conclusions: A clinically ideal concentration of mitomycin‐C would slow fibroblast proliferation yet not cause cell death to allow for a wound healing response. Mitomycin‐C 0.4 mg/mL for 4 minutes satisfies the above criteria in vitro.